FDA Reconsiders Myopia Drug, Sparking Hope in Childhood Vision Crisis

DEL MAR, CA – July 13, 2026 – The U.S. Food and Drug Administration is set to convene an expert panel to reconsider a first-of-its-kind drug for pediatric progressive myopia, a decision that could mark a turning point in addressing the rapidly growing childhood vision crisis. The move puts Sydnexis, Inc.’s investigational therapy, SYD-101, back in the spotlight after the agency initially rejected it, setting the stage for a high-stakes scientific debate over the future of children's eye health in America.

Sydnexis announced that the FDA intends to hold an Advisory Committee meeting to discuss the New Drug Application (NDA) for its low-dose atropine formulation. This development follows the company's Formal Dispute Resolution Request after receiving a Complete Response Letter (CRL) in October 2025, a formal notice of rejection. With no FDA-approved pharmaceutical options currently available in the U.S. to slow the relentless advance of nearsightedness in children, the outcome of this meeting is being watched closely by physicians, parents, and public health advocates alike.

A Regulatory Gauntlet: The Path to Approval

The journey of SYD-101 through the FDA's rigorous review process underscores the complexities of bringing novel treatments to market, especially for conditions with evolving standards of care. The CRL issued last October was a significant setback. While the FDA acknowledged that Sydnexis's pivotal Phase 3 STAR trial had met its primary endpoint, the agency concluded the data did not sufficiently demonstrate the treatment's effectiveness. Reports indicated that regulators questioned the “clinical meaningfulness” of the results and the durability of the therapeutic effect, even while raising no concerns about the drug's safety or manufacturing quality.

In response, the Del Mar-based biopharmaceutical firm initiated a formal dispute, leading to the FDA's decision to seek outside counsel from an advisory committee. These committees, composed of independent experts, provide non-binding recommendations that nonetheless carry significant weight in the agency's final decision-making. For Sydnexis, the meeting represents a critical opportunity to present its case directly to clinicians and scientists, contextualizing the data within the real-world crisis of pediatric myopia.

"We appreciate the FDA's decision to quickly convene an Advisory Committee meeting and have requested it include practicing pediatric ophthalmologists and optometrists, as they understand the long-term challenges facing patients and families every day," said Perry Sternberg, Chief Executive Officer of Sydnexis. "We believe this meeting provides an important opportunity to have a robust, science-led discussion around the totality of evidence supporting SYD-101."

The Science on Trial: Scrutinizing the STAR Study

At the heart of the debate is the Phase 3 STAR trial, the largest global clinical program ever completed for pediatric myopia. The study enrolled 847 children aged 3 to 14 and found that SYD-101 0.01% successfully met its primary endpoint, with a statistically significant reduction in the proportion of patients experiencing major progression (p=0.0226). It also met its key secondary endpoint, slowing the annual progression rate to -0.30 diopters per year compared to -0.38 for placebo (p<0.001) over 36 months.

However, the scientific landscape for low-dose atropine is complex. While widely used in East Asia, its efficacy in other populations has been debated. Some prior U.S.-based studies, including an NIH-funded trial, found 0.01% atropine was no more effective than a placebo, creating a challenging precedent for the FDA. Sydnexis has since presented subgroup analyses suggesting the drug is most effective in the patients who need it most: younger children (aged 3-12) with faster-progressing myopia. In this specific group, the treatment reduced progression by a striking 56.9% at 36 months.

This targeted benefit may be the key to its approval. One pediatric ophthalmologist not involved with the company noted that the STAR trial provides "compelling evidence that low-dose atropine can meaningfully slow myopia progression, particularly in younger children who are progressing quickly," suggesting a more nuanced, targeted treatment approach is warranted.

A Growing Epidemic and a Treatment Void

The regulatory battle is unfolding against the backdrop of a staggering public health crisis. Pediatric progressive myopia is now the most common eye disease in children, affecting nearly one-third of them worldwide. Projections are dire, with one landmark study forecasting that nearly 60% of the North American population will be myopic by 2050. This is not just a matter of needing stronger glasses; high myopia dramatically increases the lifetime risk of irreversible, blinding conditions like retinal detachment, glaucoma, and myopic maculopathy.

"Progressive myopia is rapidly becoming the most common pediatric eye disease, as more children develop the condition at younger ages and face a greater risk of serious and permanent vision complications," said Cheryl Chapman, OD, FAAO, highlighting a Citizen Petition signed by over 1,000 eye care professionals urging the FDA to expedite its review.

In the absence of an approved pharmaceutical, U.S. physicians have turned to off-label compounded low-dose atropine. While a critical stopgap, these formulations lack FDA oversight for safety, consistency, and stability. This treatment landscape has created a two-tiered system where regulated optical solutions exist—such as MiSight contact lenses and Essilor Stellest spectacle lenses—but are typically for older children, leaving a significant treatment gap for the youngest patients, who are often progressing the fastest. SYD-101, studied in children as young as three, is aimed squarely at filling that void.

"Low-dose atropine has become an essential tool for many pediatric ophthalmologists," said David G. Hunter, MD, PhD, President of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS). "Physicians, parents, and patients would benefit greatly from access to an FDA-approved option supported by consistent manufacturing standards, labeling, and heightened regulatory oversight."

The Ripple Effect: From Insurance to Global Markets

The potential approval of SYD-101 could have far-reaching implications beyond the pharmacy shelf. Currently, families often pay for compounded atropine out-of-pocket, with costs ranging from $30 to $75 per month. An FDA-approved product would be a major catalyst for insurance coverage, a push bolstered by a recent American Medical Association resolution in June 2026 that formally classified myopia as a disease and called for comprehensive coverage of evidence-based treatments.

An approval would also align the U.S. with other major markets. SYD-101 is already approved in the European Union and the United Kingdom, where it is marketed by Santen S.A. as Ryjunea®. This international precedent, combined with backing from prominent life-science investors like RA Capital and Longitude Capital, suggests strong confidence in the drug’s clinical and commercial potential.

As the FDA prepares to convene its panel, the decision on SYD-101 has become more than a review of a single drug. It is a referendum on how the nation will confront a modern epidemic that is literally changing how its children see the world.